T2 Biosystems is a developer of a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single instrument. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Its initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need.

The Company is utilizing its proprietary T2 Magnetic Resonance platform to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.

Type
Public
HQ
Lexington, US
Founded
2006
Size (employees)
178 (est)
T2 Biosystems was founded in 2006 and is headquartered in Lexington, US
Report incorrect company information

Key People/Management at T2 Biosystems

Tom Lowery

Tom Lowery

Vice President of Diagnostics Research & Development
Rahul Dhanda

Rahul Dhanda

Vice President of Global Support Services Marketing

T2 Biosystems Office Locations

T2 Biosystems has offices in Lexington and Wilmington
Lexington, US (HQ)
101 Hartwell Ave
Wilmington, US
231 Andover St
Show all (2)
Report incorrect company information

T2 Biosystems Financials and Metrics

T2 Biosystems Financials

T2 Biosystems's revenue was reported to be $4.67 m in FY, 2017
USD

Revenue (Q1, 2018)

2.3 m

EBIT (Q1, 2018)

(11.4 m)

Market capitalization (23-May-2018)

315.5 m

Closing share price (23-May-2018)

8.8

Cash (31-Mar-2018)

29.7 m

EV

368.4 m
T2 Biosystems's current market capitalization is $315.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

119 k2.8 m4.1 m4.7 m

Revenue growth, %

2264%45%

General and administrative expense

11 m19.1 m24.1 m22.8 m

R&D expense

19.8 m25.4 m24 m23.7 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

188 k564 k1 m1.1 m990 k1.1 m941 k956 k2.3 m

General and administrative expense

4.5 m4.4 m5.2 m6.2 m6.1 m5.9 m5.9 m5.8 m5.8 m

R&D expense

5.9 m6.7 m6.2 m6.6 m6.4 m5.2 m6.6 m7.1 m4.7 m

Operating expense total

10.3 m11.1 m12.2 m13.8 m14.3 m13 m14.1 m14.9 m13.7 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

73.8 m73.7 m73.5 m41.8 m

Accounts Receivable

201 k369 k327 k467 k

Inventories

115 k683 k820 k1.3 m

Current Assets

75.3 m75.6 m75.4 m44.3 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

65.3 m53.3 m40.1 m59.5 m50.2 m75.1 m58.8 m46.1 m29.7 m

Accounts Receivable

88 k389 k378 k360 k288 k379 k409 k981 k582 k

Inventories

252 k569 k1.1 m1.3 m1.4 m1.3 m489 k1 m2.1 m

Current Assets

66.4 m54.9 m42.7 m62 m52.5 m77.8 m60.7 m48.8 m33 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(31.4 m)(45.3 m)(54.8 m)(62.4 m)

Depreciation and Amortization

691 k1.5 m2.3 m2.9 m

Inventories

(1.2 m)(568 k)(110 k)

Accounts Payable

(208 k)177 k(61 k)(314 k)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(10.6 m)(21.6 m)(11.6 m)(12.9 m)

Depreciation and Amortization

600 k629 k

Inventories

252 k(453 k)1.1 m1.3 m1.4 m64 k

Accounts Payable

720 k725 k1.2 m827 k993 k1.6 m795 k895 k1.2 m132 k
USDY, 2018

EV/EBIT

-32.2 x

EV/CFO

-31.4 x

Financial Leverage

-4.2 x
Show all financial metrics

T2 Biosystems Operating Metrics

T2 Biosystems's Patent Applications was reported to be 50 in FY, 2016.
FY, 2016

Facilities

2

Patent Applications

50

Patents Issued

50
Show all operating metrics
Report incorrect company information

T2 Biosystems News and Updates

Report incorrect company information